Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4797387 | 0.90 | ACHE (0.46) | L3MBTL1MAPTALDH1A1HTTMAPK1 | |
| SCHEMBL20456543 | 0.76 | L3MBTL1 (0.68) | L3MBTL1MAPTALDH1A1HTTMAPK1 | |
| SCHEMBL14273445 | 0.75 | ALDH1A1 (0.52) | L3MBTL1MAPTALDH1A1HTTKMT2A | |
| SCHEMBL15266902 | 0.73 | L3MBTL1 (0.63) | L3MBTL1MAPTALDH1A1MAPK1KMT2A | |
| SCHEMBL27976453 | 0.73 | AKR1C3 (0.85) | L3MBTL1MAPTALDH1A1HTTMAPK1 | |
| SCHEMBL4582126 | 0.72 | AR (0.51) | MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL21852247 | 0.72 | ALDH1A1 (0.63) | L3MBTL1MAPTALDH1A1MAPK1KMT2A | |
| SCHEMBL632352 | 0.72 | L3MBTL1 (0.73) | L3MBTL1MAPTALDH1A1HTTMAPK1 | |
| SCHEMBL4182066 | 0.72 | L3MBTL1 (0.73) | L3MBTL1MAPTALDH1A1HTTMAPK1 | |
| SCHEMBL2767534 | 0.71 | DRD2 (0.81) | L3MBTL1MAPTALDH1A1HTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1897864-A1 | Anthracene derivatives and the use thereof for treating benign and malignant tumors | AEterna Zentaris GmbH (DE) | 2008-03-12 | — | — | EP | claimed |
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2008-02-28 | — | — | US | claimed |
| EP-1897864-A1 | Anthracene derivatives and the use thereof for treating benign and malignant tumors | AEterna Zentaris GmbH (DE) | 2008-03-12 | — | — | EP | disclosed |
| EP-1897864-A1 | Anthracene derivatives and the use thereof for treating benign and malignant tumors | AEterna Zentaris GmbH (DE) | 2008-03-12 | — | — | EP | disclosed |
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2008-02-28 | — | — | US | disclosed |
| WO-2008015265-A1 | ANTHRACEN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF BENIGN AND MALIGNANT TUMOROUS DISEASES | ÆTERNA ZENTARIS GMBH (DE) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | TUBB1, TUBA1C, TUBB3 | L3MBTL1 4086/4885MAPT 85/4885ALDH1A1 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.